Dissolution Test Failure Prompts Recall of Anagrelide Capsules
Teva is voluntarily recalling a single lot of Anagrelide Capsules, USP 0.5mg, due to dissolution failure that was detected during a routine stability test.
Teva is voluntarily recalling a single lot of Anagrelide Capsules, USP 0.5mg, due to dissolution failure that was detected during a routine stability test.
The designation is based on findings from the phase 3 EMPEROR-Preserved trial.
The approval is indicated for individuals 16 years of age and older, however the vaccine remains available to those aged 12 years and older under the EUA.
Primary effectiveness of no additional surgical or interventional procedures related to the device and acceptable heart blood flow function at 6 months, was achieved by 89.2%.
Haymarket Medical Network, a part of business media company Haymarket Media, Inc., is proud to join the Ad Council’s first ever Private Marketplace (PMP) along with other partners Cadreon, The Trade Desk and Acxiom.
The American Board of Internal Medicine (ABIM) announced that certified physicians who have a Maintenance of Certification (MOC) requirement due in 2020 will now have until the end of 2021 to complete it.
Remunity is indicated for continuous subcutaneous delivery of Remodulin to treat pulmonary arterial hypertension in patients ≥22 years of age.
The designation is based on data from a phase 2 trial that included 116 patients with confirmed Staphylococcus aureus bacteremia including endocarditis.
AstraZeneca is discontinuing a phase 3 trial evaluating Epanova in patients with mixed dyslipidemia who are at high risk of CVD.
Caroline O. Pardo, Ph.D., General Manager for Haymarket Medical Education, is pleased to announce that HME, based in Paramus, NJ, has been accredited as a provider of interprofessional continuing education by the Accreditation Council for Continuing Medical Education, the Accreditation Council for Pharmacy Education, and the American Nursing Credentialing Center.